Nivolumab as an adjuvant for oesophageal and gastroesophageal junction cancer

被引：1
|
作者：
Chartier, Julie [1 ]
Coutzac, Clelia [2 ]
机构：
[1] Hop Cochin, Dept Oncol Med, 123 Blvd Port Royal, F-75014 Paris, France
[2] Ctr Leon Berard, Dept Oncol Med, 28 Rue Laennec, F-69008 Lyon, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 04期
关键词：
Esophageal and gastroesophageal junction cancer; Immune checkpoint inhibitor; PD-1; Nivolumab; MULTICENTER;
D O I：
10.1016/j.bulcan.2021.11.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：389 / 390
页数：2
相关论文
共 50 条
  • [1] Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
    Kelly, Ronan J.
    Ajani, Jaffer A.
    Kuzdzal, Jaroslaw
    Zander, Thomas
    Van Cutsem, Eric
    Piessen, Guillaume
    Mendez, Guillermo
    Feliciano, Josephine
    Motoyama, Satoru
    Lievre, Astrid
    Uronis, Hope
    Elimova, Elena
    Grootscholten, Cecile
    Geboes, Karen
    Zafar, Syed
    Snow, Stephanie
    Ko, Andrew H.
    Feeney, Kynan
    Schenker, Michael
    Kocon, Piotr
    Zhang, Jenny
    Zhu, Lili
    Lei, Ming
    Singh, Prianka
    Kondo, Kaoru
    Cleary, James M.
    Moehler, Markus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1191 - 1203
  • [2] Adjuvant nivolumab for resected gastroesophageal cancer
    不详
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (06) : 368 - 368
  • [3] PHARMACOECONOMIC ANALYSIS OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER IN SWITZERLAND
    Oniangue-Ndza, C.
    Strittmatter, G.
    Lucas, A.
    Wilson, M.
    Kassahun, S.
    Singh, P.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [4] ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning
    Schneider, Bryan J.
    Chang, Andrew C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (05) : 2735 - 2738
  • [5] Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small
    Mengato, Daniele
    Chiumente, Marco
    Messori, Andrea
    [J]. JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (01) : 9 - 10
  • [6] Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small
    Daniele Mengato
    Marco Chiumente
    Andrea Messori
    [J]. Journal of Gastrointestinal Cancer, 2023, 54 : 9 - 10
  • [7] ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning
    Bryan J. Schneider
    Andrew C. Chang
    [J]. Annals of Surgical Oncology, 2022, 29 : 2735 - 2738
  • [8] Model-based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer
    Zhao, Yue
    Tsujimoto, Akihide
    Ide, Takafumi
    Zhang, Jenny
    Feng, Yan
    Gao, Ling
    Bello, Akintunde
    Roy, Amit
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024,
  • [9] A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
    Casabianca, Paul
    Massetti, Marc
    Cotte, Francois-Emery
    Moreau, Romain
    Kassahun, Sarah
    Singh, Prianka
    Kim, Inkyu
    Gaudin, Anne-Francoise
    Piessen, Guillaume
    Leleu, Henri
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 689 - 699
  • [10] EXPOSURE RESPONSE ANALYSES OF NIVOLUMAB AS ADJUVANT TREATMENT FOR PATIENTS WITH ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER (CHECKMATE 577).
    Zhao, Y.
    Tsujimoto, A.
    Ide, T.
    Zhu, L.
    Zhang, J.
    Feng, Y.
    Gao, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S60 - S60
12345